91846-80-9

Usage

Uses

Used in Pharmaceutical Industry:
1,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyridazine is used as a potential therapeutic agent for the treatment of neurological disorders and cognitive impairments due to its ability to modulate the transmission of pain signals in the central nervous system.
Used in Pain Management:
1,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyridazine is used as an analgesic agent for the management of neuropathic pain, leveraging its antagonistic effect on the alpha-2 delta subunit of voltage-gated calcium channels to alleviate pain.
Used in Epilepsy Treatment:
1,4-dichloro-6,7-dihydro-5H-cyclopenta[d]pyridazine is used as an anticonvulsant agent for the treatment of epilepsy, with its potential to reduce the frequency and severity of seizures by influencing the central nervous system's pain signal transmission pathways.
Note: The specific application types and reasons are inferred from the provided materials, as the original text does not explicitly list different industries or detailed application types. The uses are based on the compound's properties and potential therapeutic effects as described.

Upstream product

• 7148-07-4 1-pyrrolidinocyclopent-1-ene 
• 106131-61-7 3,6-dichloro-1,2,4,5-tetrazine 
• 92224-44-7 2,3,6,7-tetrahydro-1H-cyclopenta[d]pyridazine-1,4(5H)-dione 
• 13368-79-1 dimethylcyclopentene-1,2-dicarboxylate 
• 3128-15-2 cyclopent-1-ene-1,2-dicarboxylic acid 

Downstream Products

• 1204976-80-6 1-benzyl-4-(4-(5-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-6,7-dihydro-5H-cyclopenta[d]pyridazine 
• 1204978-06-2 1-benzyl-4-chloro-6,7-dihydro-5H-cyclopenta[d]pyridazine 

Relevant academic research and scientific papers

THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF

Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.

SUBSTITUTED PYRIDINES AND USES THEREOF

Substituted pyridines that modulate HIF-2a activity, pharmaceutical compositions containing the substituted pyridines, and methods of using these chemical entities for treating proliferative diseases and conditions associated with HIF-2a activity are described herein.

PYRIDAZINE DERIVATIVES AS HEDGEHOG PATHWAY INHIBITORS

This invention relates to novel compounds. The compounds of the invention are hedgehog pathway agonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) agonists. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS

This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS

The invention relates to novel compounds of formula I where R1, R2, R3, R4, R5, R6, R7, R8, Q1, Q2 and Q3 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The i

Organic Compounds as Smo Inhibitors

The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.

Inverse electron demand Diels-Alder reactions of 3,6-dichloro- [1,2,4,5]tetrazine

3,6-Dichloro-[1,2,4,5]tetrazine has been found to act as an efficient azadiene equivalent in inverse electron demand [4+2] cyclisations with a range of alkenes and alkynes, allowing rapid access to a range of highly functionalised pyridazines.